{"transactions":[{"id":861876,"issuer":{"id":62843,"kind":"organization","name":"Ventyx Biosciences, Inc.","symbol":"VTYX"},"owners":[{"id":62845,"kind":"person","name":"Moore Matthew Richard","position":1,"cik":"0001840191","reported_name":"Moore Matthew Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-04T21:30:34.000Z","date":"2026-03-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":320000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the \"Merger Agreement\"), by and among Ventyx Biosciences, Inc. (\"Issuer\") , Eli Lilly and Company (\"Parent\"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( \"Merger Sub\"), the Merger Sub merged with and into the Issuer (the \"Merger\"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger (the \"Effective Time\"), this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal to $14.00 (without interest) per share (the \"Per Share Price\") and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger (the \"Effective Time\"), this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal to $14.00 (without interest) per share (the \"Per Share Price\") and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":4.98,"expiration_date":"2034-05-16","underlying":"Common Stock","underlying_shares":320000},"source":{"system":"sec-edgar","filing":"0001840191-26-000002","document":"form4-03042026_090329.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1851194/000184019126000002/form4-03042026_090329.xml","form_type":"4"}},{"id":861875,"issuer":{"id":62843,"kind":"organization","name":"Ventyx Biosciences, Inc.","symbol":"VTYX"},"owners":[{"id":62845,"kind":"person","name":"Moore Matthew Richard","position":1,"cik":"0001840191","reported_name":"Moore Matthew Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-04T21:30:34.000Z","date":"2026-03-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":145000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the \"Merger Agreement\"), by and among Ventyx Biosciences, Inc. (\"Issuer\") , Eli Lilly and Company (\"Parent\"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( \"Merger Sub\"), the Merger Sub merged with and into the Issuer (the \"Merger\"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger (the \"Effective Time\"), this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal to $14.00 (without interest) per share (the \"Per Share Price\") and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger (the \"Effective Time\"), this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal to $14.00 (without interest) per share (the \"Per Share Price\") and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":2.14,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":145000},"source":{"system":"sec-edgar","filing":"0001840191-26-000002","document":"form4-03042026_090329.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851194/000184019126000002/form4-03042026_090329.xml","form_type":"4"}},{"id":1315149,"issuer":{"id":62843,"kind":"organization","name":"Ventyx Biosciences, Inc.","symbol":"VTYX"},"owners":[{"id":62845,"kind":"person","name":"Moore Matthew Richard","position":1,"cik":"0001840191","reported_name":"Moore Matthew Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-03T23:53:25.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":145000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One forty-eighth (1/48th) of the total shares subject to the Option shall vest each month following the Vesting Commencement Date (as defined below) on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each such date. The Vesting Commencement Date is January 2, 2025."}],"balance_after":145000,"derivative":{"exercise_price":2.14,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":145000},"source":{"system":"sec-edgar","filing":"0001415889-25-000648","document":"form4-01032025_110122.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851194/000141588925000648/form4-01032025_110122.xml","form_type":"4"}},{"id":1511699,"issuer":{"id":62843,"kind":"organization","name":"Ventyx Biosciences, Inc.","symbol":"VTYX"},"owners":[{"id":62845,"kind":"person","name":"Moore Matthew Richard","position":1,"cik":"0001840191","reported_name":"Moore Matthew Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-17T20:20:47.000Z","date":"2024-05-16","kind":"grant","planned":false,"acquired":true,"shares":320000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). \"Vesting Commencement Date\" shall mean May 16, 2024."}],"balance_after":320000,"derivative":{"exercise_price":4.98,"expiration_date":"2034-05-16","underlying":"Common Stock","underlying_shares":320000},"source":{"system":"sec-edgar","filing":"0001415889-24-013502","document":"form4-05172024_080532.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851194/000141588924013502/form4-05172024_080532.xml","form_type":"4"}},{"id":1527369,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":62845,"kind":"person","name":"Moore Matthew Richard","position":1,"cik":"0001840191","reported_name":"Moore Matthew Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-05-03T20:29:15.000Z","date":"2024-05-02","kind":"sale","planned":true,"acquired":false,"shares":4681,"price":8.7378,"value":40901.6418,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the RSUs, the shares were sold upon the vesting of the RSUs solely to cover applicable tax withholding."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction was executed in multiple trades in prices ranging from $8.47 to $9.07, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":145505,"source":{"system":"sec-edgar","filing":"0001787306-24-000072","document":"wk-form4_1714768141.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000072/wk-form4_1714768141.xml","form_type":"4"}},{"id":1527368,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":62845,"kind":"person","name":"Moore Matthew Richard","position":1,"cik":"0001840191","reported_name":"Moore Matthew Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-05-03T20:29:15.000Z","date":"2024-05-01","kind":"grant","planned":true,"acquired":true,"shares":4166,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\"), initial grant on February 22, 2024, that were subject to a performance-based vesting condition, that was determined to be satisfied on the Vesting Commencement Date, May 1, 2024."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs will vest in twelve equal quarterly installments on the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer on each vesting date."}],"balance_after":150186,"source":{"system":"sec-edgar","filing":"0001787306-24-000072","document":"wk-form4_1714768141.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000072/wk-form4_1714768141.xml","form_type":"4"}},{"id":1590692,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":62845,"kind":"person","name":"Moore Matthew Richard","position":1,"cik":"0001840191","reported_name":"Moore Matthew Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-03-06T22:08:24.000Z","date":"2024-03-04","kind":"sale","planned":true,"acquired":false,"shares":3468,"price":11.1212,"value":38568.3216,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $11.000 to $11.3200, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":146020,"source":{"system":"sec-edgar","filing":"0001787306-24-000036","document":"wk-form4_1709762890.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000036/wk-form4_1709762890.xml","form_type":"4"}},{"id":1640476,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":62845,"kind":"person","name":"Moore Matthew Richard","position":1,"cik":"0001840191","reported_name":"Moore Matthew Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-15T23:47:43.000Z","date":"2024-02-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, performance-based option granted to the Reporting Person on January 19, 2021, and deemed earned on August 29, 2023, and received in exchange for the option, these RSUs that vest in eight equal quarterly installments commencing May 1, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The canceled option vested as to 1/48 of the shares vest on each monthly anniversary of the milestone vesting commencement date, beginning on September 29, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":28.72,"expiration_date":"2031-01-18","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001787306-24-000022","document":"wk-form4_1708040852.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000022/wk-form4_1708040852.xml","form_type":"4"}},{"id":1640475,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":62845,"kind":"person","name":"Moore Matthew Richard","position":1,"cik":"0001840191","reported_name":"Moore Matthew Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-15T23:47:43.000Z","date":"2024-02-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":39500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 2, 2023, and received in exchange for the option, these RSUs that vest in twelve equal quarterly installments commencing May 1, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The canceled option vested as to 1/48 of the shares vest on each monthly anniversary measured from March 1, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":15.82,"expiration_date":"2033-03-02","underlying":"Common Stock","underlying_shares":39500},"source":{"system":"sec-edgar","filing":"0001787306-24-000022","document":"wk-form4_1708040852.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000022/wk-form4_1708040852.xml","form_type":"4"}},{"id":1640474,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":62845,"kind":"person","name":"Moore Matthew Richard","position":1,"cik":"0001840191","reported_name":"Moore Matthew Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-15T23:47:43.000Z","date":"2024-02-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":35300,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 3, 2022, and received in exchange for the option, these RSUs that vest in eight equal quarterly installments commencing May 1, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The canceled option vested as to 1/48 of the shares vest on each monthly anniversary measured from March 1, 2022 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":17.67,"expiration_date":"2032-03-03","underlying":"Common Stock","underlying_shares":35300},"source":{"system":"sec-edgar","filing":"0001787306-24-000022","document":"wk-form4_1708040852.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000022/wk-form4_1708040852.xml","form_type":"4"}},{"id":1640473,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":62845,"kind":"person","name":"Moore Matthew Richard","position":1,"cik":"0001840191","reported_name":"Moore Matthew Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-15T23:47:43.000Z","date":"2024-02-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":80000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on January 19, 2021, and received in exchange for the option, these Restricted Stock Units (\"RSUs\") that vest in eight equal quarterly installments commencing May 1, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The canceled option vested as to 1/4 of the total shares on January 11, 2022, and then 1/48 of the total shares vest monthly thereafter, with 100% of the total shares vesting on January 11, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":28.72,"expiration_date":"2031-01-19","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001787306-24-000022","document":"wk-form4_1708040852.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000022/wk-form4_1708040852.xml","form_type":"4"}},{"id":1640472,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":62845,"kind":"person","name":"Moore Matthew Richard","position":1,"cik":"0001840191","reported_name":"Moore Matthew Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-15T23:47:43.000Z","date":"2024-02-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":80000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on January 19, 2021, and received in exchange for the option, these Restricted Stock Units (\"RSUs\") that vest in eight equal quarterly installments commencing May 1, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The canceled option vested as to 1/4 of the total shares on July 20, 2021, and then 1/48 of the total shares vest monthly thereafter, with 100% of the total shares vesting on July 20, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":28.72,"expiration_date":"2031-01-19","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001787306-24-000022","document":"wk-form4_1708040852.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000022/wk-form4_1708040852.xml","form_type":"4"}},{"id":1640471,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":62845,"kind":"person","name":"Moore Matthew Richard","position":1,"cik":"0001840191","reported_name":"Moore Matthew Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-02-15T23:47:43.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":4166,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, performance-based option granted to the Reporting Person on January 19, 2021, and deemed earned on August 29, 2023, and received in exchange for the option, these RSUs that vest in eight equal quarterly installments commencing May 1, 2024."}],"balance_after":149488,"source":{"system":"sec-edgar","filing":"0001787306-24-000022","document":"wk-form4_1708040852.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000022/wk-form4_1708040852.xml","form_type":"4"}},{"id":1640470,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":62845,"kind":"person","name":"Moore Matthew Richard","position":1,"cik":"0001840191","reported_name":"Moore Matthew Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-02-15T23:47:43.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":19750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 2, 2023, and received in exchange for the option, these RSUs that vest in twelve equal quarterly installments commencing May 1, 2024."}],"balance_after":145322,"source":{"system":"sec-edgar","filing":"0001787306-24-000022","document":"wk-form4_1708040852.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000022/wk-form4_1708040852.xml","form_type":"4"}},{"id":1640469,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":62845,"kind":"person","name":"Moore Matthew Richard","position":1,"cik":"0001840191","reported_name":"Moore Matthew Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-02-15T23:47:43.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":17650,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 3, 2022, and received in exchange for the option, these RSUs that vest in eight equal quarterly installments commencing May 1, 2024."}],"balance_after":125572,"source":{"system":"sec-edgar","filing":"0001787306-24-000022","document":"wk-form4_1708040852.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000022/wk-form4_1708040852.xml","form_type":"4"}},{"id":1640468,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":62845,"kind":"person","name":"Moore Matthew Richard","position":1,"cik":"0001840191","reported_name":"Moore Matthew Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-02-15T23:47:43.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":26666,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on January 19, 2021, and received in exchange for the option, these Restricted Stock Units (\"RSUs\") that vest in eight equal quarterly installments commencing May 1, 2024."}],"balance_after":107922,"source":{"system":"sec-edgar","filing":"0001787306-24-000022","document":"wk-form4_1708040852.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000022/wk-form4_1708040852.xml","form_type":"4"}},{"id":1640467,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":62845,"kind":"person","name":"Moore Matthew Richard","position":1,"cik":"0001840191","reported_name":"Moore Matthew Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-02-15T23:47:43.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":26666,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on January 19, 2021, and received in exchange for the option, these Restricted Stock Units (\"RSUs\") that vest in eight equal quarterly installments commencing May 1, 2024."}],"balance_after":81256,"source":{"system":"sec-edgar","filing":"0001787306-24-000022","document":"wk-form4_1708040852.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000022/wk-form4_1708040852.xml","form_type":"4"}},{"id":1677458,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":62845,"kind":"person","name":"Moore Matthew Richard","position":1,"cik":"0001840191","reported_name":"Moore Matthew Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-17T21:28:52.000Z","date":"2024-01-12","kind":"grant","planned":false,"acquired":true,"shares":126000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":126000,"derivative":{"exercise_price":3.64,"expiration_date":"0034-01-12","underlying":"Common Stock","underlying_shares":126000},"source":{"system":"sec-edgar","filing":"0001787306-24-000004","document":"wk-form4_1705526921.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000004/wk-form4_1705526921.xml","form_type":"4"}},{"id":1677457,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":62845,"kind":"person","name":"Moore Matthew Richard","position":1,"cik":"0001840191","reported_name":"Moore Matthew Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-01-17T21:28:52.000Z","date":"2024-01-12","kind":"grant","planned":false,"acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute Restricted Stock Units (\"RSUs\")  for which the Reporting Person is entitled to receive one (1) share of common stock  for each one (1) RSU upon vesting.  25% of the RSUs vest annually on February 1, (the \"Vesting Commencement Date\"), of each year, beginning on February 1, 2025, subject to the Reporting Person's continued service to the issuer."}],"balance_after":54590,"source":{"system":"sec-edgar","filing":"0001787306-24-000004","document":"wk-form4_1705526921.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000004/wk-form4_1705526921.xml","form_type":"4"}},{"id":1782635,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":62845,"kind":"person","name":"Moore Matthew Richard","position":1,"cik":"0001840191","reported_name":"Moore Matthew Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-12T11:39:50.000Z","date":"2023-08-29","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"1/48th of the shares vest on each monthly anniversary of the milestone vesting commencement date, beginning on September 29, 2023,  subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares vest on each monthly anniversary of the milestone vesting commencement date, beginning on September 29, 2023,  subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":12500,"derivative":{"exercise_price":28.72,"expiration_date":"2031-01-18","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001787306-23-000092","document":"wk-form4_1694518782.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000092/wk-form4_1694518782.xml","form_type":"4"}},{"id":1968065,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":62845,"kind":"person","name":"Moore Matthew Richard","position":1,"cik":"0001840191","reported_name":"Moore Matthew Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-06T23:54:26.000Z","date":"2023-03-02","kind":"grant","acquired":true,"shares":39500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from March 2, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":39500,"derivative":{"exercise_price":15.82,"expiration_date":"2033-03-02","underlying":"Common Stock","underlying_shares":39500},"source":{"system":"sec-edgar","filing":"0001567619-23-004543","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761923004543/doc1.xml","form_type":"4"}},{"id":1968064,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":62845,"kind":"person","name":"Moore Matthew Richard","position":1,"cik":"0001840191","reported_name":"Moore Matthew Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-03-06T23:54:26.000Z","date":"2023-03-02","kind":"grant","acquired":true,"shares":14900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting. 25% of the RSUs vest annually on March 2 of each year, beginning March 2, 2024, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":26590,"source":{"system":"sec-edgar","filing":"0001567619-23-004543","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761923004543/doc1.xml","form_type":"4"}},{"id":1968063,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":62845,"kind":"person","name":"Moore Matthew Richard","position":1,"cik":"0001840191","reported_name":"Moore Matthew Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-03-06T23:54:26.000Z","date":"2023-03-02","kind":"sale","acquired":false,"shares":21,"price":16.52,"value":346.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":11690,"source":{"system":"sec-edgar","filing":"0001567619-23-004543","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761923004543/doc1.xml","form_type":"4"}},{"id":1968062,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":62845,"kind":"person","name":"Moore Matthew Richard","position":1,"cik":"0001840191","reported_name":"Moore Matthew Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-03-06T23:54:26.000Z","date":"2023-03-02","kind":"sale","acquired":false,"shares":1589,"price":15.8177,"value":25134.3253,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $15.470 to $16.460, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":11711,"source":{"system":"sec-edgar","filing":"0001567619-23-004543","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761923004543/doc1.xml","form_type":"4"}},{"id":2346903,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":62845,"kind":"person","name":"Moore Matthew Richard","position":1,"cik":"0001840191","reported_name":"Moore Matthew Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-08T01:46:37.000Z","date":"2022-03-03","kind":"grant","acquired":true,"shares":35300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from March 3, 2022 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":35300,"derivative":{"exercise_price":17.67,"expiration_date":"2032-03-03","underlying":"Common Stock","underlying_shares":35300},"source":{"system":"sec-edgar","filing":"0001567619-22-006491","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761922006491/doc1.xml","form_type":"4"}},{"id":2346902,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":62845,"kind":"person","name":"Moore Matthew Richard","position":1,"cik":"0001840191","reported_name":"Moore Matthew Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and Chief Business Officer"}}],"security":"Common Stock","published_at":"2022-03-08T01:46:37.000Z","date":"2022-03-03","kind":"grant","acquired":true,"shares":13300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting. 25% of the RSUs vest annually on March 3 of each year, beginning March 3, 2023, subject to the Reporting Person's continued service to the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 13,300 RSUs."}],"balance_after":13300,"source":{"system":"sec-edgar","filing":"0001567619-22-006491","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761922006491/doc1.xml","form_type":"4"}},{"id":2900113,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":62845,"kind":"person","name":"Moore Matthew Richard","position":1,"cik":"0001840191","reported_name":"Moore Matthew Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-22T01:07:38.000Z","date":"2021-01-19","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests as to 1/4th of the total shares on January 11, 2022, and then 1/48th of the total shares monthly thereafter, with 100% of the total shares vested on January 11, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":80000,"derivative":{"exercise_price":28.72,"expiration_date":"2031-01-19","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001567619-21-001353","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761921001353/doc1.xml","form_type":"4"}},{"id":2900112,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":62845,"kind":"person","name":"Moore Matthew Richard","position":1,"cik":"0001840191","reported_name":"Moore Matthew Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-22T01:07:38.000Z","date":"2021-01-19","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/4th of the total shares on July 20, 2021, and then 1/48th of the total shares monthly thereafter, with 100% of the total shares vested on July 20, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":80000,"derivative":{"exercise_price":28.72,"expiration_date":"2031-01-19","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001567619-21-001353","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000156761921001353/doc1.xml","form_type":"4"}}]}